Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Source of Raw Materials of Generics Should Be Disclosed: JMA
June 16, 2008
- 5 Products with Expected Sales of Over \10 Bil. to Be Listed
June 16, 2008
- Industry Needs New Drug Pricing System: Mr Shoda
June 16, 2008
- Further Increase Use of Generics: Fiscal System Council
June 16, 2008
- Sutent Drug of Choice for Progressive RCC
June 9, 2008
- GENERICS NEWS IN BRIEF
June 9, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 9, 2008
- Pharma Industry Must Be Trusted by the Public: Dr Takenaka
June 9, 2008
- Mr Shoda to Lead JPMA to Create Innovation-Friendly NHI Pricing System
June 9, 2008
- Combined Sales Exceed \6 Tril. Mark for 23 TSE 1st Section Companies
June 9, 2008
- TOPICS：Mr Kise of ATOL Elected President of Wholesalers' Fair Trade Council
June 9, 2008
- BUSINESS RESULTS
June 9, 2008
- Combined Sales of 4 Top Wholesalers Exceed \6 Tril.
June 9, 2008
- Teijin to Defend Top Market Share for Drugs for Osteoporosis: Mr Nishikawa
June 9, 2008
- Marketing Excellence Japan 2008
June 9, 2008
- Erbitux, Thymoglobulin, Mycobutin Recommended for Approval
June 9, 2008
- FJPWA Sets Common Goal for Price Agreement Rate at 70% by End Sept.
June 9, 2008
- Galderma's Adapalene, INO Therapeutics' Inoflow Recommended for Approval
June 9, 2008
- NPhA Members Exchange Opinions with Major Wholesalers
June 9, 2008
- Approval Recommended for OTC Version of Miconazole for Vaginal Candidiasis
June 9, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…